Immutep (IMMP) Other Working Capital Changes (2015 - 2026)
Immutep's (IMMP) quarterly Other Working Capital Changes came in at $4.6 million in Q2 2026, up 978.87% quarter-over-quarter from -$521485.7 in Q2 2017.
Powered by 
Analysis
Immutep (IMMP) Other Working Capital Changes (2015 - 2026) Analysis & Trends
Immutep (IMMP) has reported Other Working Capital Changes for 4 consecutive years, with $4.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Working Capital Changes changed N/A year-over-year to $4.6 million; the trailing twelve-month figure through Jun 2026 stood at $3.1 million (changed N/A YoY), and the FY2026 full-year result was $4.6 million, changed N/A from the prior year.
- Other Working Capital Changes advanced to $4.6 million in Q2 2026 per IMMP's latest filing, from -$521485.7 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $4.6 million in Q2 2026 and bottomed at $4.6 million in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.13 Bn | 193.14 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.53 Bn | 176.35 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.46 Bn | 123.61 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.89 Bn | 73.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.12 Bn | 55.94 Bn | 1.37 Bn |
| 6 | Moderna | 53.31 Bn | 48.17 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.36 Bn | 30.05 Bn | 992.69 Mn |
| 8 | Biogen | 31.72 Bn | 30.43 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.32 Bn | 29.32 Bn | 1.16 Mn |
| 10 | Immutep | 48.57 Mn | 48.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.58 Mn |
| Jun 30, 2026 | 4.58 Mn |
| Jun 30, 2017 | -521,485.70 |
| Jun 30, 2017 | -521,485.70 |
| Jun 30, 2016 | -884,199.45 |
| Jun 30, 2016 | -884,199.45 |
| Jun 30, 2015 | -111,998.64 |
| Jun 30, 2015 | -111,998.64 |